Excitement Grows for Implantica's RefluxStop® at AFS Meeting Ahead of FDA Approval

Implantica's RefluxStop® Creating Buzz at the American Foregut Society Meeting

Implantica AG, a cutting-edge medtech company, has recently set the stage for its innovative RefluxStop® device at the American Foregut Society Annual Meeting held in Dallas. This groundbreaking treatment for gastroesophageal reflux disease (GERD) has garnered immense enthusiasm from over 600 healthcare professionals, including top foregut surgeons and gastroenterologists, ahead of its anticipated FDA approval.

As discussions flourished at the meeting, the RefluxStop® device became a focal point for independent presentations led by some of the nation's leading experts. The spirited educational panel on RefluxStop® attracted nearly 120 specialists, well exceeding expected attendance, and was characterized by palpable enthusiasm and curiosity about the device's capabilities.

Accelerating Towards FDA Approval

Currently awaiting FDA approval, the RefluxStop® device promises to revolutionize the treatment of GERD, a condition that affects over 73 million individuals in the U.S. alone. The company reports a significant wave of interest from surgeons domestically and internationally, as they finalize the third module of their premarket approval (PMA) application. Implantica is actively preparing for a seamless U.S. market entry by building necessary infrastructure and resources to support a swift rollout once approval is granted.

Dr. John Lipham, a respected figure in upper gastrointestinal surgery and the panel's moderator, expressed his optimism regarding the RefluxStop® device. He highlighted the impressive results from a five-year clinical study showcasing long-term outcomes consistent with real-world data from Europe. According to Dr. Lipham, the innovative nature of RefluxStop® aligns with the latest scientific recommendations for creating an effective anti-reflux barrier.

Unique Mechanism of Action

The RefluxStop® device distinguishes itself from conventional GERD treatments by not encircling the esophagus, which typically leads to adverse side effects such as difficulty swallowing and the inability to belch. Instead, it operates by restoring the lower esophageal sphincter to its natural state, supporting the body’s intrinsic mechanisms to combat acid reflux without additional pressure on the esophagus.

During the engaging panel discussions, participants explored the unique design and efficacy of RefluxStop® which aims to reconstruct the three critical components of the anti-reflux barrier. This comprehensive approach is anticipated to enhance the standard of care in treating GERD, moving away from traditional methods that often result in complications.

Positive Feedback from Experts

Among the experts present were Dr. Peter Kahrilas from Northwestern University and Dr. Tripp Buckley, a leader in esophageal disorders at the University of Texas. They contributed to the lively discussions on RefluxStop®, emphasizing its potential to fill a significant gap in effective and minimally invasive GERD treatments.

Dr. Peter Forsell, the founder and CEO of Implantica, expressed his gratitude towards the dedicated surgeons who contributed clinical data for RefluxStop®. He noted how this collaborative effort is crucial in ushering in a new era of anti-reflux surgery, with RefluxStop® leading the charge.

With ample positive feedback from leading medical professionals at the AFS meeting, Implantica remains poised to meet the growing demand for innovative gastrointestinal solutions. "With excellent patient outcomes and enthusiasm from top specialists, we believe RefluxStop® can set a new standard for GERD treatment, not just in the U.S. but globally," Dr. Forsell concluded.

For further inquiries about RefluxStop® or Implantica, interested parties can contact Chief Corporate Affairs Officer Nicole Pehrsson.

In conclusion, the excitement surrounding RefluxStop® at the American Foregut Society meeting signals a promising future for GERD treatment, with hopes high for FDA approval and a transformative impact on patient care.